Range Financial Group LLC Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Range Financial Group LLC acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 7,385 shares of the specialty pharmaceutical company's stock, valued at approximately $917,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in JAZZ. Barclays PLC lifted its position in Jazz Pharmaceuticals by 19.1% during the third quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock valued at $4,369,000 after buying an additional 6,289 shares during the period. Choreo LLC lifted its position in Jazz Pharmaceuticals by 58.2% during the fourth quarter. Choreo LLC now owns 2,954 shares of the specialty pharmaceutical company's stock valued at $363,000 after buying an additional 1,087 shares during the period. Bleakley Financial Group LLC lifted its position in Jazz Pharmaceuticals by 52.5% during the fourth quarter. Bleakley Financial Group LLC now owns 3,112 shares of the specialty pharmaceutical company's stock valued at $383,000 after buying an additional 1,071 shares during the period. Moloney Securities Asset Management LLC purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at $464,000. Finally, Thompson Investment Management Inc. increased its holdings in shares of Jazz Pharmaceuticals by 8.2% during the fourth quarter. Thompson Investment Management Inc. now owns 7,220 shares of the specialty pharmaceutical company's stock valued at $889,000 after acquiring an additional 550 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on JAZZ. HC Wainwright raised their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a report on Monday, March 10th. Piper Sandler restated an "overweight" rating and set a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the company from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their price target for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $184.00.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded down $0.21 during trading hours on Thursday, reaching $110.29. 673,268 shares of the company traded hands, compared to its average volume of 833,423. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market cap of $6.80 billion, a P/E ratio of 15.53, a P/E/G ratio of 1.04 and a beta of 0.33. The firm has a 50-day moving average price of $107.66 and a 200 day moving average price of $120.75.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same period in the previous year, the firm earned $2.68 earnings per share. The firm's quarterly revenue was down .5% on a year-over-year basis. As a group, sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 500 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $107.90, for a total transaction of $53,950.00. Following the transaction, the chief executive officer now owns 438,473 shares of the company's stock, valued at approximately $47,311,236.70. The trade was a 0.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Seamus Mulligan bought 100,000 shares of the business's stock in a transaction dated Friday, May 9th. The shares were bought at an average cost of $98.26 per share, for a total transaction of $9,826,000.00. Following the transaction, the director now owns 100,000 shares in the company, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 3,000 shares of company stock valued at $355,925 in the last quarter. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.